Horizon Discovery plc Institutional ownership
What is the Institutional ownership of Horizon Discovery plc?
The Institutional ownership of Horizon Discovery Group plc is 59.19%
What is the definition of Institutional ownership?
Institutional Ownership is the amount of a company’s available stock owned by mutual or pension funds, insurance companies, investment firms, endowments or other large entities that manage funds on the behalf of others.
Given the considerable sums of money that institutions invest, it is not surprising that they tend to be much more knowledgeable than the average investor when it comes to the companies and industries in which they have invested.
Institutional portfolio managers often meet personally with a company's top executives, and in many cases the research they conduct is further supported by equity analysts who evaluate prospective companies and industries in great depth before making specific investment recommendations.
Institutional ownership of companies in the Health Care sector on LSE compared to Horizon Discovery plc
What does Horizon Discovery plc do?
Horizon Discovery Group plc, a cell engineering company, engages in the design, manufacture, and application of gene editing and gene modulation tools in the United Kingdom, the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company operates through Screening, Research Reagents, Diagnostics, and BioProduction segments. It provides custom-made and off-the-shelf (OTS) RNAi gene modulation reagents, CRISPR reagents, synthetic SGRNAs, OTS cell models, and custom cell engineering services. The company also offers pooled CRISPR screens; arrayed RNAi and CRISPR screens, drug screens, and immunology assays; and RNAi and CRISPR screening libraries; and human T-Cell CRISPR screening service to meet the requirements of immunology based research in drug discovery. In addition, it provides OTS gene-edited CHO cells and custom CHO cell lines, and custom CHO gene engineering services; and OTS cell-based reference standards, made to order reference standards, and custom cell-based reference standards to evaluate molecular assays on a research use basis. The company serves customers in academic research labs, biopharmaceutical and diagnostics companies, and contract research and manufacturing organizations. It sells its products through direct field sales channel and e-commerce platform. The company has a partnership with the Rutgers, The State University of New Jersey to develop and commercialize base editing, a gene editing technology; strategic collaboration with Mammoth Biosciences to develop CRISPR tools to provide engineered cell lines for the biopharmaceutical industry; and collaboration with St George's University Hospital, London, and the European Molecular Genetics Quality Network to develop reference material for non-invasive prenatal testing. Horizon Discovery Group plc was founded in 2007 and is headquartered in Cambridge, the United Kingdom.
Companies with institutional ownership similar to Horizon Discovery plc
- TKH NV has Institutional ownership of 59.03%
- JD Wetherspoon Plc has Institutional ownership of 59.03%
- Schroder Real Estate Investment Trust has Institutional ownership of 59.05%
- Farmer Bros. Co has Institutional ownership of 59.08%
- Lakeland has Institutional ownership of 59.08%
- Renewi Plc has Institutional ownership of 59.15%
- Horizon Discovery plc has Institutional ownership of 59.19%
- Foghorn Therapeutics has Institutional ownership of 59.20%
- Lightspeed POS has Institutional ownership of 59.21%
- Empiric Student Property PLC has Institutional ownership of 59.26%
- China Industrial Securities International has Institutional ownership of 59.26%
- Peridot Acquisition has Institutional ownership of 59.27%
- CTO Realty Growth Inc has Institutional ownership of 59.27%